Panel recommendations for CNL
| Disease . | Panel recommendations . |
|---|---|
| CNL (WHO/ICC) | All patients with CNL should be assessed early following diagnosis for potential transplant eligibility and donor search Treatment aimed at optimizing disease control (control of leukocytosis, reduction in splenomegaly, where relevant) is recommended as a “bridge” before transplant, balancing the risks and benefits Given limited data, no recommendations can be made on optimal transplant conditioning regimens and posttransplant disease monitoring and maintenance. However, consideration needs to be given to considerable relapse rates and approaches tailored accordingly. |
| Disease . | Panel recommendations . |
|---|---|
| CNL (WHO/ICC) | All patients with CNL should be assessed early following diagnosis for potential transplant eligibility and donor search Treatment aimed at optimizing disease control (control of leukocytosis, reduction in splenomegaly, where relevant) is recommended as a “bridge” before transplant, balancing the risks and benefits Given limited data, no recommendations can be made on optimal transplant conditioning regimens and posttransplant disease monitoring and maintenance. However, consideration needs to be given to considerable relapse rates and approaches tailored accordingly. |